Comparative Efficacy and Safety of Adjunctive 0.015% Triamcinolone Acetonide Topical Spray With Lokivetmab Versus Lokivetmab Monotherapy as ‘Reactive Therapy’ for Canine Atopic Dermatitis: A Randomised, Single‐Blinded, Controlled Preliminary Trial
Frane Banovic, Michaela Austel, Lauren Johnson, Cristiano von SimsonABSTRACT
Background
Lokivetmab is considered an effective systemic therapy for dogs with atopic dermatitis (AD); however, utilisation of lokivetmab with adjunctive topical anti‐inflammatory glucocorticoids has not been investigated in canine AD.
Objectives
To evaluate the efficacy and safety of the combination therapy of lokivetmab and 0.015% triamcinolone acetonide (TCA) spray in dogs with AD.
Animals
Twenty dogs with nonseasonal AD.
Materials and Methods
This study was a randomised, single‐blinded (investigators only) 4‐week controlled trial. Dogs were randomised to receive lokivetmab monotherapy or lokivetmab‐TCA spray per manufacturer instructions. Clinical assessments included the Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI‐04), CADESI‐04E (i.e., extracted erythema grade alone) and the 10‐grade pruritus Visual Analog Scale (PVAS10) at Day (D)0, D14 and D28. Complete blood count and serum biochemical analysis were performed on D0 and D28.
Results
The median CADESI‐04 and CADESI‐04E scores in the lokivetmab‐TCA group were significantly reduced on D14 ( p < 0.05 for both) and D28 ( p < 0.01 for both) compared to baseline; there were no significant differences in lesional scores at any time point for the lokivetmab monotherapy group. Lokivetmab‐TCA significantly reduced CADESI‐04E values compared to the lokivetmab monotherapy group on D28 ( p = 0.04). Both interventions significantly reduced PVAS10 scores on D14 and D28 compared to D0 ( p < 0.05 for both groups).
Conclusions and Clinical Relevance
Topical application of TCA spray may be a useful and safe adjunctive therapy for systemic lokivetmab to alleviate pruritus and clinical lesions in the initial management of canine AD patients.